Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. B.S. SUSPENSION [SIN00526P]

B.S. SUSPENSION [SIN00526P]

Active ingredients: B.S. SUSPENSION

Last updated 26 October 2025

Product Info

B.S. SUSPENSION

[SIN00526P]

Product information

Active Ingredient and Strength

SULPHAMETHOXAZOLE - 200 MG/5 ML
TRIMETHOPRIM - 40 MG/5 ML

Dosage Form

SUSPENSION

Manufacturer and Country

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD - MALAYSIA

Registration Number

SIN00526P

Licence Holder

APEX PHARMA MARKETING PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J01EE01

Indications
Treatment of infections caused by susceptible organisms, as in: respiratory tract infections, urinary tract infections, gastro-intestinal tract infections, including typhoid and paratyphoid fever; cholera; skin and soft tissues infections; brucellosis (generally in combination with other agents), septicaemia due to sensitive organisms, nocardiosis, mycetoma (except when caused by the true fungi). For South American blastomycosis, BS is suppressive but not curative.

Dosage and Administration
To be administered orally.

Table caption

By body weight:

6 mg Trimethoprim plus 30mg
Sulphamethoxazole per kg body weight per day

Children 6 weeks to 5 months:

2.5 ml, every 12 hours

6 months to 5 years:

5 ml, every 12 hours

6 to 12 years:

10 ml, every 12 hours.

Contraindications
BS should not be used in patients with marked liver parenchymal damage; severe renal insufficiency; or patients with serious megaloblastic bone marrow; or patients with documented megaloblastic anemia due to folate deficiency.
BS is contraindicated in patients with a known hypersensitivity to trimethoprim or sulphonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.
Its use in pregnancy should be avoided, unless the expected therapeutic benefits outweigh the possible risks. BS should not be used in nursing mothers. BS is contraindicated in premature and newborn infants within 1 to 2 months of birth because of the risk of producing kernicterus.